Page data last changed: . Chemistry registry snapshot: . Registry refreshes and identity assessments are separate from scientific content review.
A GLP-1 agonist fused to albumin — half-life extension by protein engineering rather than a fatty-acid chain.
Also known as: Tanzeum · Eperzan
Part of the Metabolic & GLP-1 peptides cluster
Overview
Albiglutide is a GLP-1 receptor agonist created by genetically fusing two modified GLP-1 sequences to human serum albumin, giving it a long half-life suited to once-weekly dosing. Approved as Tanzeum and Eperzan in 2014, it was later withdrawn from the market for commercial reasons and is now a historical case study.
Source & context
Biological / chemical source: Recombinant fusion of two GLP-1 dimers to human serum albumin
Primary research or clinical context: Previously approved (EU and United States); withdrawn from the market for commercial reasons
Half-life by albumin fusion
Rather than attaching a fatty-acid side chain like semaglutide, albiglutide fuses its GLP-1 sequence directly to albumin — the most abundant, long-lived protein in blood. The GLP-1 portion is also modified for DPP-4 resistance. This makes it a distinct illustration of the fusion-protein approach to extending peptide half-life.
Approval and withdrawal
Albiglutide was an approved prescription medicine before its manufacturer withdrew it from the global market for economic reasons, with supplies depleted by 2018. It is described here as a regulated, now-discontinued product for educational context only, not as an available treatment.
Structure & chemistry
Molecular identity & reference confidence
Source-supported reference
Reference values are taken from the cited molecular record or curated profile. A database match is not independent laboratory verification; modifications, counter-ions, and formulations can change the measured mass.
- Molecular form
- Albiglutide (source record; form not independently established)
- Species
- Not established by this molecular identity audit
- Termini (N / C)
- Not specified / Not specified
Average reference mass
Reference policy updated: 2026-10-05
- IUPHAR/BPS source snapshot · 2026-10-01
- PubChem molecular record · 2026-10-01
- Molecular formula
- C148H223N39O46
- Average reference mass
- ≈ 3,284.6
- Status
- Approved medicine in at least one jurisdiction (IUPHAR record)
- PubChem CID: 122173812
- IUPHAR ligand: 7386
- ChEMBL: CHEMBL2107841
- CAS RN: 782500-75-8
- UNII: 5E7U48495E
Chemistry values: PubChem, IUPHAR/BPS Guide to Pharmacology · fetched 2026-10-01.
Clinical development snapshot
ClinicalTrials.gov lists 39 registered studies with “Albiglutide” as an intervention (snapshot 2026-09-06). A registry footprint is not evidence of efficacy or approval.
| NCT | Title | Phase | Status | Updated |
|---|---|---|---|---|
| NCT05220917 | Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study | — | active not recruiting | 2026-08-13 |
| NCT07188545 | Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascu | — | active not recruiting | 2025-09-23 |
| NCT03492580 | A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failu | — | completed | 2025-06-25 |
| NCT06449235 | Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh | Phase 4 | unknown | 2024-07-16 |
| NCT02787551 | Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor A | Phase 3 | completed | 2022-03-25 |
| NCT02229227 | Safety and Efficacy of Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine Subjects With T | Phase 3 | completed | 2020-11-27 |
Albiglutide — reconstitution calculator
Enter how much peptide is in the vial and how much diluent (e.g. bacteriostatic water) is added. The tool returns the resulting solution concentration — and, for any amount you type, the volume it corresponds to. This is educational arithmetic, not a dosing recommendation.
Reference form: Albiglutide (source record; form not independently established)Average reference mass: 3,284.6 Da
Enter an amount to see the volume it corresponds to.
Educational concentration mathematics only. This tool does not recommend a dose, amount, or protocol, and nothing here is medical advice. Many peptides are not authorized by Health Canada for human use — see our reconstitution and bacteriostatic-water guides for context.
FAQ about Albiglutide
What is Albiglutide?+
Albiglutide is a GLP-1 receptor agonist created by genetically fusing two modified GLP-1 sequences to human serum albumin, giving it a long half-life suited to once-weekly dosing. Approved as Tanzeum and Eperzan in 2014, it was later withdrawn from the market for commercial reasons and is now a historical case study.
What Canadian product status is recorded for Albiglutide?+
Canadian product status for Albiglutide has not been verified in this profile. No verified record here does not mean no authorization exists. Status depends on the product, formulation and use; consult Health Canada's product records.
What is the typical length of Albiglutide?+
Albiglutide is not a classic amino-acid chain peptide in the same sense; see the profile for classification details.
Related peptides
References & further reading
- 1.Hernandez et al. (2018). Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet
- 2.Poole et al. (2014). Albiglutide: first global approval. Drugs
- 3.Trietley et al. (2017). Albiglutide (Tanzeum) for Diabetes Mellitus. Am Fam Physician
- 4.Rhea et al. (2024). Brain uptake pharmacokinetics of albiglutide, dulaglutide, tirzepatide, and DA5-CH in the search for new treatments of Alzheimer's and Parkinson's diseases. Tissue Barriers
- 5.Muscogiuri et al. (2014). Albiglutide for the treatment of type 2 diabetes. Drugs Today (Barc)
- 6.PubChem — compound summary for Albiglutide (CID 122173812)
- 7.Wikipedia — Albiglutide